NeuroOne Q1 FY2025 revenue $6.3M, net income $1.8M; reaffirms FY guidance

NEUROONE MEDICAL TECHNOLOGIES Corp

2025-Q1 EPS reported $0.06 revenue$3,274,167

Product revenue $3.3M (+235% YoY); license revenue $3.0M from expanded Zimmer Biomet deal.
Net income $1.8M ($0.06 EPS) vs net loss of $3.3M ($0.14 loss) in prior year.
Product gross margin improved to 58.9% from 27.2%; FY2025 product revenue outlook $8-10M reaffirmed.
Regained Nasdaq compliance; debt-free with $1.1M cash and $4.1M working capital.
OneRF placed in 5 epilepsy centers; FDA 510(k) submission for trigeminal nerve ablation expected H1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.